A study to investigate how a single dose of the drug melflufen reaches brain tumor tissue, and how it affects the tumour, in patients who are already scheduled for surgery for a returning glioblastoma

Start 17 Jun 2026 · Status Authorised, recruiting · 1 EU/EEA countries · 1 sites · Protocol OP-701

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other

Status Authorised, recruiting

Participants planned 10

Countries 1

Sites 1

Recurrent glioblastoma

Key facts

Sponsor: Oncopeptides AB
Participant type: Patients
Age range: 18-64 years, 65+ years
Gender: Male and Female
Therapeutic area: Diseases [C] - Nervous System Diseases [C10], Diseases [C] - Neoplasms [C04]
Trial duration: 17 Jun 2026 → ongoing
Decision date (initial): 2026-05-15
Transition trial: No
Low-intervention: No
Rare-disease indication: Yes
Vulnerable population: No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Recurrent glioblastoma

Version	Level	Code	Term	System organ class
20.0	PT	10018336	Glioblastoma	100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Oncopeptides AB

Sponsor organisation: Oncopeptides AB
Address: 7th Floor, Luntmakargatan 46, Adolf Fredrik Luntmakargatan 46 Adolf Fredrik
City: Stockholm
Postcode: 111 37
Country: Sweden

Scientific contact point

Organisation: Oncopeptides AB
Contact name: Stefan Norin

Public contact point

Organisation: Oncopeptides AB
Contact name: Eva Nordström

Locations

1 EU/EEA country · 1 investigational sites

By country

Country	MS status	Planned subjects	Sites
Norway	Authorised, recruiting	10	1
Rest of world	—	0	—

Investigational sites

Norway

1 site · Authorised, recruiting

Oslo Universitetssykehus HF

Department of Oncology, Montebello, Ullernchausséen 70, Oslo

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country	Trial start	Trial end	Recruitment start	Recruitment end	Early termination
Norway	2026-06-17

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#	Type	Code	Submitted	Reference MS	Conclusion	Decision date
1	INITIAL	IN	2026-03-13	Norway	Acceptable 2026-05-15	2026-05-15